Molecular structure of AZD1480, CAS Number: 935666-88-9
AZD1480 (CAS 935666-88-9)
See product citations (11)
Alternate Names:
(S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
Application:
AZD1480 is an inhibitor of JAK2
CAS Number:
935666-88-9
Purity:
≥98%
Molecular Weight:
348.77
Molecular Formula:
C14H14ClFN8
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AZD1480 is a novel ATP-competitive inhibitor of JAK2 (IC50 = 0.26 nM). Janus-associated kinases (JAKs) are a group of intracellular tyrosine kinases essential for mediating the signaling of specific cytokines and growth factor receptors. AZD1480 has demonstrated potent inhibitory effects on cell growth in the presence of the V617F mutant of JAK2, with a GI50 value of 60 nM. This compound has been widely employed as a pharmacological tool to inhibit the activity of janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) in an in vitro model of upper gastrointestinal adenocarcinoma. Moreover, AZD1480 has been utilized in combination with bortezomib to investigate the role of tumor-associated macrophages in the survival of myeloma cells.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
AZD1480 (CAS 935666-88-9) References
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. | Scuto, A., et al. 2011. Leukemia. 25: 538-50. PMID: 21164517
- Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. | Xin, H., et al. 2011. Cancer Res. 71: 6601-10. PMID: 21920898
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. | Derenzini, E., et al. 2011. Blood Cancer J. 1: e46. PMID: 22829094
- AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. | Couto, JP., et al. 2012. PLoS One. 7: e46869. PMID: 23056499
- Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. | Gu, L., et al. 2013. Clin Cancer Res. 19: 5658-74. PMID: 23942095
- AZD1480 can inhibit the biological behavior of ovarian cancer SKOV3 cells in vitro. | Sun, ZL., et al. 2013. Asian Pac J Cancer Prev. 14: 4823-7. PMID: 24083752
- Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. | Murakami, T., et al. 2014. Lung Cancer. 83: 30-6. PMID: 24238495
- Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. | Houghton, PJ., et al. 2014. Pediatr Blood Cancer. 61: 1972-9. PMID: 25131802
- AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. | Maenhout, SK., et al. 2014. Oncotarget. 5: 6801-15. PMID: 25149535
- AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway. | Wang, SW., et al. 2014. Oncol Rep. 32: 1991-8. PMID: 25216185
- The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. | Jiang, X., et al. 2015. Biochem Biophys Res Commun. 458: 908-12. PMID: 25704089
- JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation. | Lu, Z., et al. 2017. J Vet Intern Med. 31: 1804-1815. PMID: 28960447
- Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480. | Gudernova, I., et al. 2017. Oncotarget. 8: 109319-109331. PMID: 29312610
- Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. | Zhang, J., et al. 2019. Am J Physiol Lung Cell Mol Physiol. 316: L487-L497. PMID: 30604628
- Improving Pneumovirus Isolation Using a Centrifugation and AZD1480 Combined Method. | Lee, H., et al. 2019. J Microbiol Biotechnol. 29: 2006-2013. PMID: 31581384
Inhibitor of:
Bpifa6, G-CSFR, IFN-γRα, IRF-3, IRF-4, JAK, JAK2, JAK3, JAKMIP2, KSHV K8α, NKG2-D, Olfr547, OTTMUSG00000011268, SCARA3, SEMA3A, SOCS-3, SOCS-6, Stat, Stat5a, Talanin, and Taok3.Activator of:
ISGF-3γ p48, and SOCS-6.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AZD1480, 5 mg | sc-364735 | 5 mg | $122.00 | |||
AZD1480, 50 mg | sc-364735A | 50 mg | $1051.00 |